President Trump Announces Second MFN Pricing Deal with AstraZeneca to Lower Drug Costs
Impact Score: 2.2
Timeline: AstraZeneca to invest $50 billion in U.S. manufacturing and R&D by 2030
Summary: President Trump announced a new Most-Favored-Nation (MFN) pricing agreement with AstraZeneca to align U.S. drug prices with the lowest costs paid by other developed countries for State Medicaid programs. This initiative aims to save hundreds of millions for nine million AstraZeneca patients and others with asthma and COPD by enforcing repatriation of foreign revenues and offering steep discounts. The deal includes AstraZeneca’s $50 billion investment in U.S. manufacturing and R&D, creating 3,600 jobs in Virginia. The policy is part of ongoing efforts to reduce American drug costs and counterbalance global pricing inequalities.
Key Actions: Vanderbilt entities should assess MFN pricing impacts on procurement, budgeting, research funding, and policy engagement; pursue partnership opportunities with AstraZeneca’s U.S. investments; and study economic and healthcare effects of the new pricing model.
View Full Report
